Effective drug delivery by PEGylated drug conjugates Export

@article{Greenwald03, abstract = {The current review presents an update of drug delivery using poly(ethylene glycol) (PEG), that focuses on recent developments in both protein and organic drugs. Certainly the past 10 years has resulted in a renaissance of the field of PEG drug conjugates, initiated by the use of higher molecular weight PEGs (Mw>20,000), especially 40,000 which is estimated to have a plasma circulating t1/2 of approximately 10 h in mice. This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models, and has led to a clinical candidate, PEG-camptothecin (PROTHECAN®), an ester based prodrug currently in phase II trials. Additional applications of high molecular weight PEG prodrug strategies to amino containing drugs are presented: similar tripartate systems based on lower Mw PEG and their use with proteins is expounded on. The modification of a benzyl elimination tripartate prodrug specific for mercaptans is presented, and its successful application to 6-mercaptopurine giving a water soluble formulation is discussed. Recent novel PEG oligonucleotides and immunoconjugates are also covered. Clinical results of FDA approved PEGylated proteins are also presented. {\copyright} 2002 Elsevier Science B.V. All rights reserved.}, address = {Enzon, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854-3969, United States}, author = {Greenwald, R. B. and Choe, Y. H. and Mcguire, J. and Conover, C. D.}, citeulike-article-id = {1572698}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/S0169-409X(02)00180-1}, citeulike-linkout-1 = {http://www.scopus.com/record/display.url?view=extended&origin=resultslist&eid=2-s2.0-0037428969}, doi = {10.1016/S0169-409X(02)00180-1}, journal = {Adv. Drug Deliv. Rev.}, keywords = {delivery, drug, pegs}, number = {2}, pages = {217--250}, posted-at = {2007-08-17 17:32:13}, priority = {3}, title = {Effective drug delivery by PEGylated drug conjugates}, url = {http://dx.doi.org/10.1016/S0169-409X(02)00180-1}, volume = {55}, year = {2003} }

TY - JOUR ID - Greenwald03 L3 - citeulike-article-id:1572698 N2 - The current review presents an update of drug delivery using poly(ethylene glycol) (PEG), that focuses on recent developments in both protein and organic drugs. Certainly the past 10 years has resulted in a renaissance of the field of PEG drug conjugates, initiated by the use of higher molecular weight PEGs (Mw>20,000), especially 40,000 which is estimated to have a plasma circulating t1/2 of approximately 10 h in mice. This recent resuscitation of small organic molecule delivery by high molecular weight PEG conjugates was founded on meaningful in vivo testing using established tumor models, and has led to a clinical candidate, PEG-camptothecin (PROTHECAN®), an ester based prodrug currently in phase II trials. Additional applications of high molecular weight PEG prodrug strategies to amino containing drugs are presented: similar tripartate systems based on lower Mw PEG and their use with proteins is expounded on. The modification of a benzyl elimination tripartate prodrug specific for mercaptans is presented, and its successful application to 6-mercaptopurine giving a water soluble formulation is discussed. Recent novel PEG oligonucleotides and immunoconjugates are also covered. Clinical results of FDA approved PEGylated proteins are also presented. © 2002 Elsevier Science B.V. All rights reserved. IS - 2 JF - Adv. Drug Deliv. Rev. AD - Enzon, Inc., 20 Kingsbridge Road, Piscataway, NJ 08854-3969, United States EP - 250 TI - Effective drug delivery by PEGylated drug conjugates VL - 55 SP - 217 KW - delivery KW - drug KW - pegs AU - Greenwald, RB AU - Choe, YH AU - Mcguire, J AU - Conover, CD PY - 2003/// UR - http://dx.doi.org/10.1016/S0169-409X(02)00180-1 ER -